Steady-state Pharmacokinetics of BIA 2-093 and Oxcarbazepine in Healthy Volunteers

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Bial - Portela C S.A.
ClinicalTrials.gov Identifier:
NCT01679002
First received: August 31, 2012
Last updated: December 31, 2014
Last verified: December 2014

August 31, 2012
December 31, 2014
October 2003
December 2003   (final data collection date for primary outcome measure)
Cmax - Maximum Observed Plasma Drug Concentration [ Time Frame: pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72 and 96 h post-dose ] [ Designated as safety issue: No ]

Cmax - maximum observed plasma drug concentration for BIA 2-093 metabolites:

BIA 2-194 BIA 2-195 Oxcarbazepine

maximum observed plasma drug concentration (Cmax) [ Time Frame: pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72 and 96 h post-dose ] [ Designated as safety issue: No ]
Pharmacokinetic parameters were derived from the concentration versus time profiles after each dose in each subject:time at which the Cmax occurred (tmax)
Complete list of historical versions of study NCT01679002 on ClinicalTrials.gov Archive Site
  • AUC - Area Under the Plasma Concentration Versus Time Curve [ Time Frame: pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72 and 96 h post-dose ] [ Designated as safety issue: No ]

    AUC - Area Under the Plasma Concentration Versus Time Curve for BIA 2-093 metabolites:

    BIA 2-194 BIA 2-195 Oxcarbazepine

  • Number of of Subjects Reporting at Least One Adverse Event [ Time Frame: 8 weeks ] [ Designated as safety issue: Yes ]
    Number of of subjects reporting at least one adverse event.
area under the plasma concentration versus time curve (AUC) [ Time Frame: pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72 and 96 h post-dose ] [ Designated as safety issue: No ]
Pharmacokinetic parameters were derived from the concentration versus time profiles after each dose in each subject: area under the plasma concentration versus time curve (AUC) to last measurable time point (AUC0-t)
Not Provided
Number of adverse events reported per patient [ Time Frame: 8 weeks ] [ Designated as safety issue: Yes ]
Monitoring of Adverse Events throughout the study: Safety was evaluated from the number of reported adverse events (AEs) by patient
 
Steady-state Pharmacokinetics of BIA 2-093 and Oxcarbazepine in Healthy Volunteers
Steady-state Pharmacokinetics of BIA 2-093 and Oxcarbazepine in Healthy Volunteers
To investigate the steady-state pharmacokinetics of once-daily and twice-daily regimens of BIA 2-093 and twice-daily regimen of Oxcarbazepine (Trileptal®) in healthy subjects and to assess the tolerability of such regimens in healthy subjects.
Single centre, open-label, randomised, three-way crossover study in 12 healthy volunteers. The study consisted of three 8-day treatment periods separated by washout periods of 10-15 days. On each of the treatment periods the volunteers received either a daily oral dose of BIA 2-093 900 mg once-daily (od), BIA 2-093 450 mg twice-daily (bid), or Oxcarbazepine (Trileptal®) 450 mg bid.
Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Epilepsy
  • Drug: BIA 2-093
    Other Name: ESL, Eslicarbazepine acetate
  • Drug: Oxcarbazepine
    Other Name: OXC, Trileptal®
  • Experimental: Group A

    BIA 2-093 900 mg once-daily period followed by BIA 2-093 450 mg twice-daily period followed by oxcarbazepine 450 mg twice-daily period

    BIA 2-093 450 mg od - BIA 2-093 450 mg bid - OXC 900 mg bid

    Interventions:
    • Drug: BIA 2-093
    • Drug: Oxcarbazepine
  • Experimental: Group B

    BIA 2-093 450 mg twice-daily period followed by oxcarbazepine 450 mg twice-daily period followed by BIA 2-093 900 mg once-daily period

    BIA 2-093 450 mg bid - OXC 450 mg bid - BIA 2-093 900 mg od

    Interventions:
    • Drug: BIA 2-093
    • Drug: Oxcarbazepine
  • Experimental: Group C

    oxcarbazepine 450 mg twice-daily period followed by BIA 2-093 900 mg once-daily period followed by BIA 2-093 450 mg twice-daily period

    OXC 450 mg bid - BIA 2-093 900 mg od - BIA 2-093 450 mg bid

    Interventions:
    • Drug: BIA 2-093
    • Drug: Oxcarbazepine
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
12
December 2003
December 2003   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subjects were eligible for entry into the study if they fulfilled the following inclusion criteria:
  • Male or female subjects aged between 18 and 45 years, inclusive.
  • Subjects of body mass index (BMI) between 19 and 28 kg/m2, inclusive.
  • Subjects who were healthy as determined by pre-study medical history, physical examination, neurological examination, and 12-lead ECG.
  • Subjects who had clinical laboratory tests clinically acceptable.
  • Subjects who were negative for HBsAg, anti-HCV Ab and HIV-1 and HIV-2 Ab tests at screening.
  • Subjects who were negative for alcohol and drugs of abuse at screening and first admission.
  • Subjects who were non-smokers or who smoked less than 10 cigarettes or equivalent per day.
  • Subjects who were able and willing to give written informed consent.
  • If case of female subjects, subjects who were not of childbearing potential by reason of surgery or, if of childbearing potential, who used one of the following methods of contraception: double-barrier, intrauterine device or abstinence.
  • If case of female subjects, subjects who had a negative pregnancy test at screening and first admission.

Exclusion Criteria:

  • Subjects who did not conform to the above inclusion criteria.
  • Subjects who had a clinically relevant history or presence of respiratory, gastrointestinal, renal, hepatic, haematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, endocrine, connective tissue diseases or disorders.
  • Subjects who had a clinically relevant surgical history.
  • Subjects who had a clinically relevant family history.
  • Subjects who had a history of relevant atopy.
  • Subjects who had a history of hypersensitivity to carbamazepine or oxcarbazepine or any other relevant drug hypersensitivity.
  • Subjects who had a history of alcoholism or drug abuse.
  • Subjects who consumed more than 14 units of alcohol a week.
  • Subjects who had a significant infection or known inflammatory process on screening and/or first admission.
  • Subjects who had acute gastrointestinal symptoms at the time of screening and/or first admission (e.g., nausea, vomiting, diarrhoea, heartburn).
  • Subjects who had used prescription or over-the-counter medication within two weeks of first admission.
  • Subjects who had used any investigational drug and/or participated in any clinical trial within four months of their first admission.
  • Subjects who had previously received BIA 2-093.
  • Subjects who had donated and/or received any blood or blood products within the previous 4 months prior to screening.
  • Subjects who were vegetarians, vegans and/or have medical dietary restrictions.
  • Subjects who could not communicate reliably with the investigator.
  • Subjects who were unlikely to co-operate with the requirements of the study.
  • Subjects who were unwilling or unable to give written informed consent.
  • In case of female subjects, subjects who were pregnant or breast-feeding.
  • In case of female subjects, subjects who were of childbearing potential and did not use an approved effective contraceptive method or used oral contraceptives.
Both
18 Years to 45 Years   (Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
Portugal
 
NCT01679002
BIA-2093-110
No
Not Provided
Not Provided
Bial - Portela C S.A.
Bial - Portela C S.A.
Not Provided
Principal Investigator: Manuel Vaz-da-Silva, MD, PhD BIAL - Portela & Cª S.A.
Bial - Portela C S.A.
December 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP